ReviewJournal of thrombosis and thrombolysis2011
The many faces of the contact pathway and their role in thrombosis.
Review in Journal of thrombosis and thrombolysis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Factor XI as a new target for prevention of thromboembolism in cardiovascular disease: a meta-analysis of randomized controlled trials.Journal of thrombosis and thrombolysis · 2025Pooled it
- RNA interference targeting factor XI: new and novel approach.Blood advances · 2026Article
- Factor XI and Cancer: Physiopathological Linkage and Clinical Perspectives.Journal of clinical medicine · 2025Review
- Factor XI levels and the risk of cardiovascular events: a systematic review and meta-analysis of case-control and cohort studies.Research and practice in thrombosis and haemostasis · 2025Article
- Factor XI: structure, function and therapeutic inhibition.Journal of thrombosis and thrombolysis · 2024Review
- The Contrasting Effects ofToxins · 2024Article
- Rapid molecular imaging of active thrombiMolecular therapy. Nucleic acids · 2023Article
- Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study.Anesthesiology · 2022Observational
- Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO.Molecular therapy. Nucleic acids · 2022Article
- Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.Cell chemical biology · 2022Article
- Factor Xa inhibitors: critical considerations for clinical development and testing.Journal of thrombosis and thrombolysis · 2021Review
- Kallikrein Cleaves C3 and Activates Complement.Journal of innate immunity · 2018Article
- Establishing a protocol for thromboelastography in sea turtles.Veterinary record open · 2018Article
- Role of Vascular Endothelial Cells in Disseminated Intravascular Coagulation Induced by Seawater Immersion in a Rat Trauma Model.BioMed research international · 2017Article
- Microparticle analysis in disorders of hemostasis and thrombosis.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2016Review
- The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats.PloS one · 2016Article
- Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation.Journal of thrombosis and haemostasis : JTH · 2015Article
- Factor XI and contact activation as targets for antithrombotic therapy.Journal of thrombosis and haemostasis : JTH · 2015Review
- Murine models in the evaluation of heparan sulfate-based anticoagulants.Methods in molecular biology (Clifton, N.J.) · 2015Article
- Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay.Thrombosis research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding inherent differences between thrombosis and hemostasis in the vascular system are critical to developing safe and effective anticoagulants. To this end, constituents of the contact activated and intrinsic pathway of coagulation appear to be involved in pathological thrombus formation, but are not required for normal hemostasis. In addition to coagulation, activation of the contact system is involved in fibrinolytic, inflammatory, and angiogenic processes that can also contribute to the thrombotic environment. This review discusses the role of the contact system in these processes, and highlights the potential of FXII and FXI as safer targets for antithrombotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.